Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 2/20 | 0.37 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.37 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.37 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.37 |
| ▸ | GABRA3 | P34903 | 2/20 | 0.37 |
| ▸ | GABRA2 | P47869 | 2/20 | 0.37 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.34 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.34 |
| ▸ | GRM5 | P41594 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1306384 | 0.87 | GABRA1 (0.38) | GABRA1GABRG2GABRB3GABRA5GABRA3 | |
| SCHEMBL1306505 | 0.85 | APP (0.41) | GABRA1GABRG2GABRB3GABRA5GABRA3 | |
| SCHEMBL2854252 | 0.80 | CYP1A1 (0.44) | GABRA1GABRG2GABRB3GABRA5GABRA3 | |
| SCHEMBL19174201 | 0.78 | CYP1A1 (0.48) | GABRA1GABRG2GABRB3GABRA5GABRA3 | |
| SCHEMBL440124 | 0.78 | GRM5 (0.50) | GABRA1GABRG2GABRB3GABRA5GABRA3 | |
| SCHEMBL853691 | 0.76 | CYP2A6 (0.48) | — | |
| SCHEMBL613688 | 0.76 | MAOA (0.39) | GABRA1GABRG2GABRB3GABRA5GABRA3 | |
| SCHEMBL1230904 | 0.76 | GABRA1 (0.37) | GABRA1GABRG2GABRB3GABRA5GABRA3 | |
| SCHEMBL1230907 | 0.76 | APP (0.48) | GABRA1GABRG2GABRB3GABRA5GABRA3 | |
| SCHEMBL3347257 | 0.76 | GRM5 (0.48) | GABRA1GABRG2GABRB3GABRA5GABRA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080161269-A1 | Compounds 620 | ASTRAZENECA AB (SE) | 2008-07-03 | — | — | US | disclosed |
| US-20080161269-A1 | Compounds 620 | ASTRAZENECA AB (SE) | 2008-07-03 | — | — | US | disclosed |
| WO-2008076045-A1 | NOVEL 2-AMINO- 5-ARYL-IMIDAZOL-4 -ONES | ASTRAZENECA AB (SE) | 2008-06-26 | — | — | WO | disclosed |
| EP-1215247-B1 | Curable polysiloxane compositions | WACKER CHEMIE GMBH (DE) | 2005-03-09 | — | — | EP | disclosed |
| US-6566430-B2 | Crosslinking; molding materials | WACKER-CHEMIE GMBH (DE) | 2003-05-20 | — | — | US | disclosed |
| US-20020111426-A1 | Curable organopolysiloxane compositions | WACKER-CHEMIE GMBH (DE) | 2002-08-15 | — | — | US | disclosed |
| EP-1215247-A1 | Curable polysiloxane compositions | Wacker-Chemie GmbH (DE) | 2002-06-19 | — | — | EP | disclosed |
| US-6359098-B1 | SHELF LIFE AS ONE-COMPONENT ADDITION-CURABLE ORGANOPOLYSILOXANES, AND EXTENDED POT LIFE FOR TWO-COMPONENT ADDITION-CURABLE ORGANOPOLYSILOXANES, WITHOUT COMPROMISING CROSSLINKING RATES OR LEVELS | WACKER-CHEMIE GMBH (DE) | 2002-03-19 | — | — | US | disclosed |
| EP-1077226-B1 | Curable Polysiloxane Compositions | WACKER CHEMIE GMBH (DE) | 2002-01-23 | — | — | EP | disclosed |
| EP-1077226-A1 | Curable Polysiloxane Compositions | Wacker-Chemie GmbH (DE) | 2001-02-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080161269-A1 | Compounds 620 | MAPT, PSEN1, PSEN2 | GABRA1 831/4885GABRG2 1144/4885GABRB3 601/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.